The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Cancer Immunotherapy: The Dawn of the Renaissance after the Medieval Dark Ages

종양면역치료: 중세 암흑시대에서 르네상스시대로

  • Lee, Dae Ho (Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center)
  • 이대호 (울산대학교 의과대학 서울아산병원 종양내과)
  • Published : 2014.09.01
⟨ Previous Next ⟩

Abstract

Cancer immunotherapy has come a long way since William Coley observed that a mixture of killed bacteria, or Coley's toxin, induced tumor regression. However, enthusiasm for cancer immunotherapy has changed to skepticism over recent decades due to its lack of efficacy, inconsistency, and significant toxicity. Of course, much of that skepticism was the result of a lack of understanding of the immune system. The recent expansion of our understanding of immunity and immune system and the success of new cancer immunotherapies has raised hope that we can treat cancer effectively via immunotherapy or combination approach using immunotherapy and other cancer therapies. Indeed, there is no doubt that cancer immunotherapy is experiencing a renaissance. Here, I will briefly review the current status of various immunotherapies, including cytokine therapy, antibody therapy, cancer vaccines, and adoptive cell therapy, and then I will summarize the results of recent clinical trials using anti-immune checkpoint monoclonal antibodies.

Keywords

References

  1. McCarthy EF. The toxins of William B: coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J 2006;26:154-158.
  2. Hoption Cann SA, van Netten JP, van Netten C, Glover DW. Spontaneous regression: a hidden treasure buried in time. Med Hypotheses 2002;58:115-119. https://doi.org/10.1054/mehy.2001.1469
  3. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011;480:480-489. https://doi.org/10.1038/nature10673
  4. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-723. https://doi.org/10.1056/NEJMoa1003466
  5. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-2526. https://doi.org/10.1056/NEJMoa1104621
  6. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-2465. https://doi.org/10.1056/NEJMoa1200694
  7. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-2454. https://doi.org/10.1056/NEJMoa1200690
  8. Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma. Eur Cancer Congr 2013 (ECCO-ESMO-ESTRO); September 27-October 1, 2013; Amsterdam, The Netherlands. Abstract 24.
  9. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-144. https://doi.org/10.1056/NEJMoa1305133
  10. Hamid O, Sosman JA, Lawrence DP, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM): American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2013; Chicago, IL. J Clin Oncol 2013;31(Suppl; abstr 9010).
  11. Soria JC, Cruz C, Bahleda R, et al. Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer (NSCLC): additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PD-L1): Eur Cancer Congr 2013 (ECCO-ESMO-ESTRO); September 27-October 1, 2013; Amsterdam, The Netherlands. Abstract 3408.
  12. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-133. https://doi.org/10.1056/NEJMoa1302369
  13. Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010;102:493-501. https://doi.org/10.1093/jnci/djq009
  14. Royal RE, Steinberg SM, Krouse RS, et al. Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. Cancer J Sci Am 1996;2:91-98.
  15. Crosbie EJ, Kitchener HC. Cervarix: a bivalent L1 virus-like particle vaccine for prevention of human papillomavirus type 16- and 18-associated cervical cancer. Expert Opin Biol Ther 2007;7:391-396. https://doi.org/10.1517/14712598.7.3.391
  16. Hanna E, Bachmann G. HPV vaccination with Gardasil: a breakthrough in women's health. Expert Opin Biol Ther 2006;6:1223-1227. https://doi.org/10.1517/14712598.6.11.1223
  17. Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 2011;17:3520-3526. https://doi.org/10.1158/1078-0432.CCR-10-3126
  18. Vetsika EK, Konsolakis G, Aggouraki D, et al. Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001. Cancer Immunol Immunother 2012;61:157-168. https://doi.org/10.1007/s00262-011-1093-4
  19. Liu TY, Hussein WM, Jia Z, et al. Self-adjuvanting polymerpeptide conjugates as therapeutic vaccine candidates against cervical cancer. Biomacromolecules 2013;14:2798-2806. https://doi.org/10.1021/bm400626w
  20. Grossardt C, Engeland CE, Bossow S, et al. Granulocytemacrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine. Hum Gene Ther 2013;24:644-654. https://doi.org/10.1089/hum.2012.205
  21. Zhang X, Shi X, Li J, et al. A novel therapeutic vaccine of mouse GM-CSF surface modified MB49 cells against metastatic bladder cancer. J Urol 2012;187:1071-1079. https://doi.org/10.1016/j.juro.2011.10.126
  22. Yin W, He Q, Hu Z, et al. A novel therapeutic vaccine of GM-CSF/TNFalpha surface-modified RM-1 cells against the orthotopic prostatic cancer. Vaccine 2010;28:4937-4944. https://doi.org/10.1016/j.vaccine.2010.05.038
  23. Noguchi M, Sasada T, Itoh K. Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine. Cancer Immunol Immunother 2013;62:919-929. https://doi.org/10.1007/s00262-012-1379-1
  24. Li Y, Huang Q, Zhong Y, Wang A, Sun J, Zhou J. Prospects in adoptive cell transfer therapy for cancer. J Immunol Clin Res 2013;1:1008.
  25. Rayner AA, Grimm EA, Lotze MT, Chu EW, Rosenberg SA. Lymphokine-activated killer (LAK) cells: analysis of factors relevant to the immunotherapy of human cancer. Cancer 1985;55:1327-1333. https://doi.org/10.1002/1097-0142(19850315)55:6<1327::AID-CNCR2820550628>3.0.CO;2-O
  26. Khayat D, Weil M, Soubrane C, Jacquillat C. LAK cells and immunotherapy of cancer. Bull Cancer 1988;75:3-7.
  27. Liu J, Sui J, Zhang Z, et al. Inhibition of pleural metastasis of collecting duct carcinoma of the kidney by modified cytokine-induced killer cells: a case report and review of the literature. Oncol Lett 2010;1:955-958. https://doi.org/10.3892/ol.2010.168
  28. Li W, Xu LP, DI Zhao L, et al. Cytokine-induced killer cell therapy for advanced pancreatic adenocarcinoma: a case report and review of the literature. Oncol Lett 2013;5:1427-1429. https://doi.org/10.3892/ol.2013.1200
  29. Ma Y, Zhang Z, Tang L, et al. Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis. Cytotherapy 2012;14:483-493. https://doi.org/10.3109/14653249.2011.649185
  30. Hontscha C, Borck Y, Zhou H, Messmer D, Schmidt-Wolf IG. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 2011;137:305-310. https://doi.org/10.1007/s00432-010-0887-7
  31. Shi SB, Ma TH, Li CH, Tang XY. Effect of maintenance therapy with dendritic cells: cytokine-induced killer cells in patients with advanced non-small cell lung cancer. Tumori 2012;98:314-319.
  32. Yuanying Y, Lizhi N, Feng M, et al. Therapeutic outcomes of combining cryotherapy, chemotherapy and DC-CIK immunotherapy in the treatment of metastatic non-small cell lung cancer. Cryobiology 2013;67:235-240. https://doi.org/10.1016/j.cryobiol.2013.08.001
  33. Ren J, Di L, Song G, et al. Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences. Clin Transl Oncol 2013;15:780-788. https://doi.org/10.1007/s12094-013-1001-9
  34. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986;233:1318-1321. https://doi.org/10.1126/science.3489291
  35. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 2003;26:332-342. https://doi.org/10.1097/00002371-200307000-00005
  36. Ratto GB, Zino P, Mirabelli S, et al. A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma. Cancer 1996;78:244-251. https://doi.org/10.1002/(SICI)1097-0142(19960715)78:2<244::AID-CNCR9>3.0.CO;2-L
  37. Morgan RA, Dudley ME, Yu YY, et al. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immunol 2003;171:3287-3295. https://doi.org/10.4049/jimmunol.171.6.3287
  38. Morgan RA, Johnson LA, Davis JL, et al. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther 2012;23:1043-1053. https://doi.org/10.1089/hum.2012.041
  39. Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011;29:917-924. https://doi.org/10.1200/JCO.2010.32.2537
  40. Koehler P, Schmidt P, Hombach AA, Hallek M, Abken H. Engineered T cells for the adoptive therapy of B-cell chronic lymphocytic leukaemia. Adv Hematol 2012;2012:595060.
  41. Gill S, Porter DL. CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the road. Expert Opin Biol Ther 2014;14:37-49. https://doi.org/10.1517/14712598.2014.860442
  42. Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013;368:1365-1366. https://doi.org/10.1056/NEJMc1302338
  43. Hodi FS, Lee SJ, McDermolt DF, et al. Multicenter, randomized phase II trial of GMCSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608. J Clin Oncol 2013;31(Suppl; abstr CRA9007).
  44. Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012;30:2046-2054. https://doi.org/10.1200/JCO.2011.38.4032
  45. Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 2013;24:75-83. https://doi.org/10.1093/annonc/mds213

Cited by

  1. 국내 한의학계에 보고된 흑색종 관련 실험적 연구들의 비교 고찰 vol.28, pp.3, 2014, https://doi.org/10.6114/jkood.2015.28.3.030